Table 4 Survival results of the main clinical trials evaluating Bevacizumab as single-agent or in combination with FTM
Author (year) | Type clinical trial | Treatment | N pts | Histotype | Recurrence | mPFS (months) | PFS6 (%) | mOS (months) | DCR (%) | ORR (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Single-arm trials | ||||||||||
Kreisl (2009) [13] | Phase II | BEV | 48 | GBM | I/II/III... | 3.7 | 29 | 7.1 | NA | 35 |
Chamberlain (2010) [14] | Retrospective | BEV | 50 | GBM | I/II | 1 | 42 | 8.5 | 42 | 42 |
Raitzer (2010) [15] | Phase II | BEV | 50 | GBM | I/II/III... | 2.7 | 25 | 6.4 | NA | 25% |
Kreisl 2011 [16] | Phase II | BEV | 31 | AG | I | 2.9 | 20.9 | 12 | 69 | 43 |
Nagane (2012) [17] | Phase II | BEV | 29 | GBM | I | 3.3 | 33.9 | 10.5 | 79.3 | 27.6 |
Randomized trials (BEV arm) | ||||||||||
Friedman (2009) [8] | Phase II | BEV | 85 | GBM | I/II | 4.2 | 42.6 | 9.2 | NA | 28.2 |
Taal (2014) [40] | Phase II | BEV | 50 | GBM | I | 3 | 18 | 8 | NA | 38 |
Field (2015) [41] | Phase II | BEV | 55 | GBM | I | 3.5 | 18 | 7.5 | 64 | 6 |
Puduvalli (2015) [42] | Phase II | BEV | 41 | GBM | I | 3.6 | NA | 7 | NA | NA |
Hacibekiroglu (2015) [43] | Retrospective | BEV | 24 | MGs | I | 4.1 | 37.5 | 6.4 | 58.3 | 20.8 |
Brandes (2016) [44] | Phase II | BEV | 59 | GBM | I | 3.38 | 26.3 | 7.3 | NA | 29 |
BEV with FTM | ||||||||||
Vaccaro (2014) [20] | Observational prospective | BEV + FTM | 26 | MGs | I/II | 4 | 23.1 | 6 | 92.5 | 31 |
Soffietti (2014) [21] | Phase II | BEV + FTM | 54 | GBM | I | 5.2 | 42.6 | 9.1 | 89 | 52 |
Soffietti (2012) [23] | Phase II | BEV + FTM | 32 | AG | I | 5 | 31 | 8.6 | 94 | 50 |
Liu (2015) [22] | Retrospective | BEV + FTM | 176 | GBM | I | 5 | 33.3 | 8 | 90.9 | 46.5 |
Our study (2016) | Retrospective | BEV/BEV + FTM | 17 | MGs | I/II | 5 | 41.2 | 8.3 | 64.7 | 47.1 |